Diamond-Blackfan Anemia

Mendelian MONDO:0015253 Pathograph 13 Hematological Disease Genetic Disease

Ask OpenScientist

Ask a research question about Diamond-Blackfan Anemia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
3
Pathophys.
8
Phenotypes
13
Pathograph
10
Genes
5
Treatments
9
References
2
Deep Research
👪

Inheritance

1
Autosomal dominant HP:0000006
Autosomal dominant inheritance
Show evidence (1 reference)
PMID:20301769 SUPPORT Human Clinical
"identification of a heterozygous pathogenic variant in a gene associated with autosomal dominant DBA syndrome"
Confirms autosomal dominant as the most common inheritance pattern for DBA.
⚙

Pathophysiology

3
Ribosomal Protein Haploinsufficiency
Heterozygous loss-of-function mutations in ribosomal protein genes reduce ribosome assembly and protein synthesis capacity. Erythroid progenitors are exquisitely sensitive to ribosomal stress due to their high proliferative and translational demands. RPS19 mutations account for ~25% of cases, with RPL5, RPL11, and other RP genes collectively explaining ~65-70% of DBA.
erythroid progenitor cell link
RPS19 link RPL5 link RPL11 link RPL35A link RPS26 link RPS24 link RPS10 link RPS17 link RPS7 link
ribosome biogenesis link ↓ DECREASED translation link ↓ DECREASED translational initiation link ↓ DECREASED
Downstream
p53-Mediated Erythroid Apoptosis Ribosomal stress activates p53, leading to cell cycle arrest and apoptosis of erythroid progenitors.
Show evidence (2 references)
PMID:9988267 SUPPORT Human Clinical
"we identified mutations in RPS19 in 10 of 40 unrelated DBA patients, including nonsense, frameshift, splice site and missense mutations"
Original discovery of RPS19 mutations as the cause of DBA, establishing the ribosomal protein basis.
PMID:9988267 SUPPORT Human Clinical
"a function for RPS19 in erythropoiesis and embryogenesis"
Confirms RPS19 has specific roles in erythropoiesis and embryonic development.
p53-Mediated Erythroid Apoptosis
Ribosomal stress from RP haploinsufficiency leads to accumulation of free ribosomal proteins that bind MDM2, stabilizing p53. Activated p53 triggers cell cycle arrest and apoptosis preferentially in erythroid progenitors, resulting in selective red cell aplasia.
erythroblast link
signal transduction by p53 class mediator link ↑ INCREASED erythrocyte differentiation link ⚠ ABNORMAL
Show evidence (1 reference)
PMID:20301769 SUPPORT Human Clinical
"characterized by a profound normochromic and usually macrocytic anemia with normal leukocytes and platelets"
Confirms the selective erythroid failure (normal leukocytes and platelets) consistent with erythroid-specific apoptosis.
GATA1 Translational Insufficiency
A distinct non-ribosomal mechanism causing DBA. GATA1 is an X-linked erythroid transcription factor essential for erythroid differentiation. Mutations in GATA1 (including splice site variants) reduce functional GATA1 protein levels, impairing erythroid gene expression. Unlike ribosomal protein mutations, GATA1 mutations directly affect erythroid transcription rather than global translation, but converge on the same erythroid differentiation failure.
erythroid progenitor cell link
GATA1 link
regulation of transcription by RNA polymerase II link ⚠ ABNORMAL erythrocyte differentiation link ⚠ ABNORMAL
Show evidence (1 reference)
PMID:20301769 SUPPORT Human Clinical
"the molecular diagnosis can be established in a male proband by identification of a hemizygous pathogenic variant in GATA1 or TSR2 associated with X-linked DBA syndrome"
Confirms GATA1 as a distinct X-linked cause of DBA, separate from ribosomal protein genes.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Diamond-Blackfan Anemia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

8
Blood 4
Macrocytic Anemia VERY_FREQUENT Macrocytic anemia (HP:0001972)
Show evidence (1 reference)
PMID:20301769 SUPPORT Human Clinical
"The hematologic complications occur in 90% of affected individuals during the first year of life"
Confirms onset of anemia during the first year of life in 90% of cases.
Pure Red Cell Aplasia VERY_FREQUENT Pure red cell aplasia (HP:0012410)
Show evidence (1 reference)
PMID:9988267 SUPPORT Human Clinical
"constitutional erythroblastopenia characterized by absent or decreased erythroid precursors"
Confirms erythroblastopenia (red cell aplasia) as the defining hematologic feature.
Acute Myeloid Leukemia OCCASIONAL Acute myeloid leukemia (HP:0004808)
Show evidence (1 reference)
PMID:20301769 SUPPORT Human Clinical
"associated with an increased risk for acute myelogenous leukemia, myelodysplastic syndrome, and solid tumors including osteogenic sarcoma"
Confirms increased AML risk in DBA patients.
Myelodysplasia OCCASIONAL Myelodysplasia (HP:0002863)
Show evidence (1 reference)
PMID:20301769 SUPPORT Human Clinical
"associated with an increased risk for acute myelogenous leukemia, myelodysplastic syndrome, and solid tumors including osteogenic sarcoma"
Confirms increased MDS risk in DBA patients.
Head and Neck 1
Congenital Malformations FREQUENT Craniofacial dysostosis (HP:0004439)
Show evidence (1 reference)
PMID:20301769 SUPPORT Human Clinical
"congenital malformations in up to 50% of affected individuals"
Confirms congenital malformations in up to half of DBA patients.
Limbs 1
Triphalangeal Thumb OCCASIONAL Triphalangeal thumb (HP:0001199)
Show evidence (1 reference)
PMID:19773262 SUPPORT Human Clinical
"A close association was evident between RPL5 mutations and craniofacial malformations, and between hand malformations and RPL11 mutations"
Establishes genotype-phenotype correlation between RPL11 mutations and hand malformations including thumb anomalies.
Musculoskeletal 1
Osteosarcoma OCCASIONAL Osteosarcoma (HP:0002669)
Show evidence (1 reference)
PMID:20301769 SUPPORT Human Clinical
"associated with an increased risk for acute myelogenous leukemia, myelodysplastic syndrome, and solid tumors including osteogenic sarcoma"
Confirms increased osteosarcoma risk in DBA patients.
Growth 1
Short Stature FREQUENT Short stature (HP:0004322)
Show evidence (1 reference)
PMID:20301769 SUPPORT Human Clinical
"growth deficiency in 30% of affected individuals"
Confirms growth deficiency affects approximately 30% of DBA patients.
🧬

Genetic Associations

10
RPS19 (Causative)
Autosomal dominant
Show evidence (2 references)
PMID:9988267 SUPPORT Human Clinical
"we identified mutations in RPS19 in 10 of 40 unrelated DBA patients"
Original identification of RPS19 as the first DBA gene, mutated in ~25% of patients.
CGGV:assertion_bceef5ee-7596-4a90-91ce-b36385f9669b-2023-05-30T160000.000Z SUPPORT Other
"RPS19 | HGNC:10402 | Diamond-Blackfan anemia | MONDO:0015253 | AD | Definitive"
ClinGen classifies the RPS19-Diamond-Blackfan anemia gene-disease relationship as definitive with autosomal dominant inheritance.
RPL5 (Causative)
Autosomal dominant
Show evidence (2 references)
PMID:19773262 SUPPORT Human Clinical
"Two new genes (RPL5, RPL11), encoding for ribosomal proteins of the large subunit, have been reported to be involved in a considerable percentage of patients"
Identifies RPL5 as a DBA gene encoding a large ribosomal subunit protein.
PMID:19773262 SUPPORT Human Clinical
"About 20% of the patients screened had mutations in RPL5 or RPL11"
Quantifies RPL5/RPL11 mutation frequency at ~20% of RPS19-negative DBA patients.
RPL11 (Causative)
Autosomal dominant
Show evidence (2 references)
PMID:19773262 SUPPORT Human Clinical
"About 20% of the patients screened had mutations in RPL5 or RPL11"
Quantifies RPL11 mutation frequency in Italian DBA cohort.
PMID:19773262 SUPPORT Human Clinical
"A close association was evident between RPL5 mutations and craniofacial malformations, and between hand malformations and RPL11 mutations"
Establishes RPL11-specific genotype-phenotype correlation with hand malformations.
RPL35A (Causative)
Autosomal dominant
Show evidence (1 reference)
PMID:19773262 SUPPORT Human Clinical
"Mutations in RPS24, RPS17, and RPL35A described in a minority of patients show that Diamond-Blackfan anemia is a disorder of ribosome biogenesis"
Identifies RPL35A as a DBA gene, establishing DBA as a ribosomopathy.
RPS26 (Causative)
Autosomal dominant
RPS24 (Causative)
Autosomal dominant
RPS10 (Causative)
Autosomal dominant
RPS17 (Causative)
Autosomal dominant
RPS7 (Causative)
Autosomal dominant
GATA1 (Causative)
X-linked recessive
Show evidence (3 references)
PMID:22706301 SUPPORT Human Clinical
"We performed exome sequencing on two siblings who had no known pathogenic mutations for DBA and identified a mutation in the gene encoding the hematopoietic transcription factor GATA1"
Discovery of GATA1 as a DBA gene through exome sequencing.
PMID:22706301 SUPPORT Human Clinical
"the reduction in erythropoiesis associated with the disease can arise from causes other than defects in ribosomal protein genes"
Establishes that DBA can be caused by non-ribosomal protein gene mutations, specifically GATA1.
PMID:37973818 SUPPORT Human Clinical
"Recent studies also indicated that non-RP genes like GATA1, TSR2, are associated with DBA"
Confirms GATA1 and TSR2 as non-ribosomal protein genes associated with DBA.
💊

Treatments

5
Corticosteroid Therapy
Action: systemic corticosteroid therapy Ontology label: Systemic Corticosteroid Therapy NCIT:C122080
First-line treatment. Improves the red blood cell count in approximately 60-80% of affected individuals. Recommended to start at age 12 months or older to minimize growth effects.
Show evidence (1 reference)
PMID:20301769 SUPPORT Human Clinical
"Corticosteroid treatment, recommended in children at age 12 months or older, improves the red blood cell count in approximately 60%-80% of affected individuals"
Confirms corticosteroid efficacy at 60-80% response rate and recommended age of initiation.
Chronic Red Blood Cell Transfusions
Action: blood transfusion MAXO:0000756
Necessary during the first year of life and for steroid-nonresponders. Iron chelation therapy is required after 10-12 transfusions to prevent transfusion-related iron overload.
Show evidence (1 reference)
PMID:20301769 SUPPORT Human Clinical
"Chronic transfusion with packed red blood cells is necessary during the first year of life"
Confirms chronic transfusion as necessary during the first year to avoid steroid effects on growth.
Hematopoietic Stem Cell Transplantation
Action: hematopoietic stem cell transplantation MAXO:0000747
The only curative therapy for the hematologic manifestations of DBA. Recommended for transfusion-dependent patients or those developing other cytopenias.
Show evidence (1 reference)
PMID:20301769 SUPPORT Human Clinical
"Hematopoietic stem cell transplantation, the only curative therapy for the hematologic manifestations of DBA syndrome"
Confirms HSCT as the only curative therapy for DBA hematologic manifestations.
Iron Chelation Therapy
Action: iron chelation therapy Ontology label: chelator agent therapy MAXO:0001223
Required for transfusion-dependent patients after 10-12 transfusions. Deferasirox (oral) or deferoxamine (subcutaneous) are preferred.
Genetic Counseling
Action: genetic counseling MAXO:0000079
Important for family screening. Approximately 40-45% of cases are inherited; 55-60% are de novo.
🔬

Biochemical Markers

5
Hemoglobin (Decreased)
Context: Profound anemia; may require transfusion support
MCV (Elevated)
Context: Macrocytosis is characteristic
Erythrocyte Adenosine Deaminase (Elevated)
Context: Elevated eADA is a diagnostic biomarker for DBA
HbF (Elevated)
Context: Elevated fetal hemoglobin is a common finding
Reticulocytes (Decreased)
Context: Reticulocytopenia reflecting erythroid production failure
{ }

Source YAML

click to show 
name: Diamond-Blackfan Anemia
creation_date: '2026-02-16T18:18:28Z'
updated_date: '2026-04-22T20:13:21Z'
category: Mendelian
parents:
- Hematological Disease
- Genetic Disease
disease_term:
  preferred_term: Diamond-Blackfan anemia
  term:
    id: MONDO:0015253
    label: Diamond-Blackfan anemia
prevalence:
- population: Global
  percentage: 0.0007
  notes: >
    Approximately seven per million live births. Incidence is consistent
    across ethnicities. No sex predilection.
  evidence:
  - reference: PMID:18671700
    reference_title: "Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classical DBA affects about seven per million live births and presents during the first year of life"
    explanation: Confirms the incidence of DBA at approximately seven per million live births.
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:20301769
    reference_title: "DBA Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "identification of a heterozygous pathogenic variant in a gene associated with autosomal dominant DBA syndrome"
    explanation: Confirms autosomal dominant as the most common inheritance pattern for DBA.
pathophysiology:
- name: Ribosomal Protein Haploinsufficiency
  description: >
    Heterozygous loss-of-function mutations in ribosomal protein genes
    reduce ribosome assembly and protein synthesis capacity. Erythroid
    progenitors are exquisitely sensitive to ribosomal stress due to
    their high proliferative and translational demands. RPS19 mutations
    account for ~25% of cases, with RPL5, RPL11, and other RP genes
    collectively explaining ~65-70% of DBA.
  genes:
  - preferred_term: RPS19
    term:
      id: hgnc:10402
      label: RPS19
  - preferred_term: RPL5
    term:
      id: hgnc:10360
      label: RPL5
  - preferred_term: RPL11
    term:
      id: hgnc:10301
      label: RPL11
  - preferred_term: RPL35A
    term:
      id: hgnc:10345
      label: RPL35A
  - preferred_term: RPS26
    term:
      id: hgnc:10414
      label: RPS26
  - preferred_term: RPS24
    term:
      id: hgnc:10411
      label: RPS24
  - preferred_term: RPS10
    term:
      id: hgnc:10383
      label: RPS10
  - preferred_term: RPS17
    term:
      id: hgnc:10397
      label: RPS17
  - preferred_term: RPS7
    term:
      id: hgnc:10440
      label: RPS7
  biological_processes:
  - preferred_term: ribosome biogenesis
    modifier: DECREASED
    term:
      id: GO:0042254
      label: ribosome biogenesis
  - preferred_term: translation
    modifier: DECREASED
    term:
      id: GO:0006412
      label: translation
  - preferred_term: translational initiation
    modifier: DECREASED
    term:
      id: GO:0006413
      label: translational initiation
  cell_types:
  - preferred_term: erythroid progenitor cell
    term:
      id: CL:0000038
      label: erythroid progenitor cell
  downstream:
  - target: p53-Mediated Erythroid Apoptosis
    description: >
      Ribosomal stress activates p53, leading to cell cycle arrest
      and apoptosis of erythroid progenitors.
  evidence:
  - reference: PMID:9988267
    reference_title: "The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we identified mutations in RPS19 in 10 of 40 unrelated DBA patients, including nonsense, frameshift, splice site and missense mutations"
    explanation: Original discovery of RPS19 mutations as the cause of DBA, establishing the ribosomal protein basis.
  - reference: PMID:9988267
    reference_title: "The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a function for RPS19 in erythropoiesis and embryogenesis"
    explanation: Confirms RPS19 has specific roles in erythropoiesis and embryonic development.
- name: p53-Mediated Erythroid Apoptosis
  description: >
    Ribosomal stress from RP haploinsufficiency leads to accumulation of
    free ribosomal proteins that bind MDM2, stabilizing p53. Activated p53
    triggers cell cycle arrest and apoptosis preferentially in erythroid
    progenitors, resulting in selective red cell aplasia.
  biological_processes:
  - preferred_term: signal transduction by p53 class mediator
    modifier: INCREASED
    term:
      id: GO:0072331
      label: signal transduction by p53 class mediator
  - preferred_term: erythrocyte differentiation
    modifier: ABNORMAL
    term:
      id: GO:0030218
      label: erythrocyte differentiation
  cell_types:
  - preferred_term: erythroblast
    term:
      id: CL:0000765
      label: erythroblast
  evidence:
  - reference: PMID:20301769
    reference_title: "DBA Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "characterized by a profound normochromic and usually macrocytic anemia with normal leukocytes and platelets"
    explanation: Confirms the selective erythroid failure (normal leukocytes and platelets) consistent with erythroid-specific apoptosis.
- name: GATA1 Translational Insufficiency
  description: >
    A distinct non-ribosomal mechanism causing DBA. GATA1 is an X-linked
    erythroid transcription factor essential for erythroid differentiation.
    Mutations in GATA1 (including splice site variants) reduce functional
    GATA1 protein levels, impairing erythroid gene expression. Unlike
    ribosomal protein mutations, GATA1 mutations directly affect erythroid
    transcription rather than global translation, but converge on the same
    erythroid differentiation failure.
  genes:
  - preferred_term: GATA1
    term:
      id: hgnc:4170
      label: GATA1
  biological_processes:
  - preferred_term: regulation of transcription by RNA polymerase II
    modifier: ABNORMAL
    term:
      id: GO:0006357
      label: regulation of transcription by RNA polymerase II
  - preferred_term: erythrocyte differentiation
    modifier: ABNORMAL
    term:
      id: GO:0030218
      label: erythrocyte differentiation
  cell_types:
  - preferred_term: erythroid progenitor cell
    term:
      id: CL:0000038
      label: erythroid progenitor cell
  evidence:
  - reference: PMID:20301769
    reference_title: "DBA Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the molecular diagnosis can be established in a male proband by identification of a hemizygous pathogenic variant in GATA1 or TSR2 associated with X-linked DBA syndrome"
    explanation: Confirms GATA1 as a distinct X-linked cause of DBA, separate from ribosomal protein genes.
phenotypes:
- category: Hematological
  name: Macrocytic Anemia
  description: >
    Profound normochromic, usually macrocytic anemia. Elevated MCV and
    elevated erythrocyte adenosine deaminase activity are characteristic.
    Presents during the first year of life in ~90% of cases.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: macrocytic anemia
    term:
      id: HP:0001972
      label: Macrocytic anemia
  evidence:
  - reference: PMID:20301769
    reference_title: "DBA Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The hematologic complications occur in 90% of affected individuals during the first year of life"
    explanation: Confirms onset of anemia during the first year of life in 90% of cases.
- category: Hematological
  name: Pure Red Cell Aplasia
  description: >
    Selective failure of erythroid precursor production with absent
    or markedly decreased erythroid precursors in otherwise normal
    bone marrow.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: pure red cell aplasia
    term:
      id: HP:0012410
      label: Pure red cell aplasia
  evidence:
  - reference: PMID:9988267
    reference_title: "The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "constitutional erythroblastopenia characterized by absent or decreased erythroid precursors"
    explanation: Confirms erythroblastopenia (red cell aplasia) as the defining hematologic feature.
- category: Growth
  name: Short Stature
  description: >
    Growth deficiency present in approximately 30% of affected individuals.
    May be intrinsic to the disease or secondary to corticosteroid therapy.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:20301769
    reference_title: "DBA Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "growth deficiency in 30% of affected individuals"
    explanation: Confirms growth deficiency affects approximately 30% of DBA patients.
- category: Craniofacial
  name: Congenital Malformations
  description: >
    Congenital anomalies in up to 50% of affected individuals, including
    craniofacial (cleft palate, micrognathia), thumb anomalies
    (triphalangeal, bifid, absent), cardiac defects, and genitourinary
    anomalies.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: craniofacial dysostosis
    term:
      id: HP:0004439
      label: Craniofacial dysostosis
  evidence:
  - reference: PMID:20301769
    reference_title: "DBA Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "congenital malformations in up to 50% of affected individuals"
    explanation: Confirms congenital malformations in up to half of DBA patients.
- category: Skeletal
  name: Triphalangeal Thumb
  description: >
    Thumb anomalies including triphalangeal thumbs are one of the
    most characteristic congenital malformations in DBA. Hand
    malformations are particularly associated with RPL11 mutations.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: triphalangeal thumb
    term:
      id: HP:0001199
      label: Triphalangeal thumb
  evidence:
  - reference: PMID:19773262
    reference_title: "Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A close association was evident between RPL5 mutations and craniofacial malformations, and between hand malformations and RPL11 mutations"
    explanation: Establishes genotype-phenotype correlation between RPL11 mutations and hand malformations including thumb anomalies.
- category: Neoplastic
  name: Acute Myeloid Leukemia
  description: >
    Increased risk for acute myelogenous leukemia, a recognized
    complication of DBA.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: acute myeloid leukemia
    term:
      id: HP:0004808
      label: Acute myeloid leukemia
  evidence:
  - reference: PMID:20301769
    reference_title: "DBA Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "associated with an increased risk for acute myelogenous leukemia, myelodysplastic syndrome, and solid tumors including osteogenic sarcoma"
    explanation: Confirms increased AML risk in DBA patients.
- category: Neoplastic
  name: Myelodysplasia
  description: >
    Increased risk for myelodysplastic syndrome.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: myelodysplasia
    term:
      id: HP:0002863
      label: Myelodysplasia
  evidence:
  - reference: PMID:20301769
    reference_title: "DBA Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "associated with an increased risk for acute myelogenous leukemia, myelodysplastic syndrome, and solid tumors including osteogenic sarcoma"
    explanation: Confirms increased MDS risk in DBA patients.
- category: Neoplastic
  name: Osteosarcoma
  description: >
    Increased risk for osteogenic sarcoma, the most notable solid
    tumor associated with DBA.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: osteosarcoma
    term:
      id: HP:0002669
      label: Osteosarcoma
  evidence:
  - reference: PMID:20301769
    reference_title: "DBA Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "associated with an increased risk for acute myelogenous leukemia, myelodysplastic syndrome, and solid tumors including osteogenic sarcoma"
    explanation: Confirms increased osteosarcoma risk in DBA patients.
biochemical:
- name: Hemoglobin
  presence: Decreased
  context: Profound anemia; may require transfusion support
- name: MCV
  presence: Elevated
  context: Macrocytosis is characteristic
- name: Erythrocyte Adenosine Deaminase
  presence: Elevated
  context: Elevated eADA is a diagnostic biomarker for DBA
- name: HbF
  presence: Elevated
  context: Elevated fetal hemoglobin is a common finding
- name: Reticulocytes
  presence: Decreased
  context: Reticulocytopenia reflecting erythroid production failure
genetic:
- name: RPS19
  association: Causative
  inheritance:
  - name: Autosomal dominant
  evidence:
  - reference: PMID:9988267
    reference_title: "The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we identified mutations in RPS19 in 10 of 40 unrelated DBA patients"
    explanation: Original identification of RPS19 as the first DBA gene, mutated in ~25% of patients.
  - reference: CGGV:assertion_bceef5ee-7596-4a90-91ce-b36385f9669b-2023-05-30T160000.000Z
    reference_title: "RPS19 / Diamond-Blackfan anemia (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "RPS19 | HGNC:10402 | Diamond-Blackfan anemia | MONDO:0015253 | AD | Definitive"
    explanation: ClinGen classifies the RPS19-Diamond-Blackfan anemia gene-disease relationship as definitive with autosomal dominant inheritance.
- name: RPL5
  association: Causative
  inheritance:
  - name: Autosomal dominant
  evidence:
  - reference: PMID:19773262
    reference_title: "Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two new genes (RPL5, RPL11), encoding for ribosomal proteins of the large subunit, have been reported to be involved in a considerable percentage of patients"
    explanation: Identifies RPL5 as a DBA gene encoding a large ribosomal subunit protein.
  - reference: PMID:19773262
    reference_title: "Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "About 20% of the patients screened had mutations in RPL5 or RPL11"
    explanation: Quantifies RPL5/RPL11 mutation frequency at ~20% of RPS19-negative DBA patients.
- name: RPL11
  association: Causative
  inheritance:
  - name: Autosomal dominant
  evidence:
  - reference: PMID:19773262
    reference_title: "Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "About 20% of the patients screened had mutations in RPL5 or RPL11"
    explanation: Quantifies RPL11 mutation frequency in Italian DBA cohort.
  - reference: PMID:19773262
    reference_title: "Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A close association was evident between RPL5 mutations and craniofacial malformations, and between hand malformations and RPL11 mutations"
    explanation: Establishes RPL11-specific genotype-phenotype correlation with hand malformations.
- name: RPL35A
  association: Causative
  inheritance:
  - name: Autosomal dominant
  evidence:
  - reference: PMID:19773262
    reference_title: "Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in RPS24, RPS17, and RPL35A described in a minority of patients show that Diamond-Blackfan anemia is a disorder of ribosome biogenesis"
    explanation: Identifies RPL35A as a DBA gene, establishing DBA as a ribosomopathy.
- name: RPS26
  association: Causative
  inheritance:
  - name: Autosomal dominant
- name: RPS24
  association: Causative
  inheritance:
  - name: Autosomal dominant
- name: RPS10
  association: Causative
  inheritance:
  - name: Autosomal dominant
- name: RPS17
  association: Causative
  inheritance:
  - name: Autosomal dominant
- name: RPS7
  association: Causative
  inheritance:
  - name: Autosomal dominant
- name: GATA1
  association: Causative
  inheritance:
  - name: X-linked recessive
  evidence:
  - reference: PMID:22706301
    reference_title: "Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We performed exome sequencing on two siblings who had no known pathogenic mutations for DBA and identified a mutation in the gene encoding the hematopoietic transcription factor GATA1"
    explanation: Discovery of GATA1 as a DBA gene through exome sequencing.
  - reference: PMID:22706301
    reference_title: "Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the reduction in erythropoiesis associated with the disease can arise from causes other than defects in ribosomal protein genes"
    explanation: Establishes that DBA can be caused by non-ribosomal protein gene mutations, specifically GATA1.
  - reference: PMID:37973818
    reference_title: "Perspectives of current understanding and therapeutics of Diamond-Blackfan anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recent studies also indicated that non-RP genes like GATA1, TSR2, are associated with DBA"
    explanation: Confirms GATA1 and TSR2 as non-ribosomal protein genes associated with DBA.
treatments:
- name: Corticosteroid Therapy
  description: >
    First-line treatment. Improves the red blood cell count in approximately
    60-80% of affected individuals. Recommended to start at age 12 months
    or older to minimize growth effects.
  treatment_term:
    preferred_term: systemic corticosteroid therapy
    term:
      id: NCIT:C122080
      label: Systemic Corticosteroid Therapy
  evidence:
  - reference: PMID:20301769
    reference_title: "DBA Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Corticosteroid treatment, recommended in children at age 12 months or older, improves the red blood cell count in approximately 60%-80% of affected individuals"
    explanation: Confirms corticosteroid efficacy at 60-80% response rate and recommended age of initiation.
- name: Chronic Red Blood Cell Transfusions
  description: >
    Necessary during the first year of life and for steroid-nonresponders.
    Iron chelation therapy is required after 10-12 transfusions to prevent
    transfusion-related iron overload.
  treatment_term:
    preferred_term: blood transfusion
    term:
      id: MAXO:0000756
      label: blood transfusion
  evidence:
  - reference: PMID:20301769
    reference_title: "DBA Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chronic transfusion with packed red blood cells is necessary during the first year of life"
    explanation: Confirms chronic transfusion as necessary during the first year to avoid steroid effects on growth.
- name: Hematopoietic Stem Cell Transplantation
  description: >
    The only curative therapy for the hematologic manifestations of DBA.
    Recommended for transfusion-dependent patients or those developing
    other cytopenias.
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: MAXO:0000747
      label: hematopoietic stem cell transplantation
  evidence:
  - reference: PMID:20301769
    reference_title: "DBA Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hematopoietic stem cell transplantation, the only curative therapy for the hematologic manifestations of DBA syndrome"
    explanation: Confirms HSCT as the only curative therapy for DBA hematologic manifestations.
- name: Iron Chelation Therapy
  description: >
    Required for transfusion-dependent patients after 10-12 transfusions.
    Deferasirox (oral) or deferoxamine (subcutaneous) are preferred.
  treatment_term:
    preferred_term: iron chelation therapy
    term:
      id: MAXO:0001223
      label: chelator agent therapy
- name: Genetic Counseling
  description: >
    Important for family screening. Approximately 40-45% of cases are
    inherited; 55-60% are de novo.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
datasets:
references:
- reference: PMID:20301769
  title: "DBA Syndrome."
  tags:
  - GeneReviews
  findings: []
- reference: DOI:10.1016/j.isci.2024.109172
  title: Disruption of mitochondrial energy metabolism is a putative pathogenesis of Diamond-Blackfan anemia
  findings: []
- reference: DOI:10.1016/j.jbc.2024.107542
  title: Activation of nemo-like kinase in diamond blackfan anemia suppresses early erythropoiesis by preventing mitochondrial biogenesis
  findings: []
- reference: DOI:10.1038/s41375-023-02082-w
  title: Perspectives of current understanding and therapeutics of Diamond-Blackfan anemia
  findings: []
- reference: DOI:10.1038/s41392-024-02033-6
  title: BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK signaling
  findings: []
- reference: DOI:10.1172/jci.insight.171650
  title: Lentivirus-mediated gene therapy corrects ribosomal biogenesis and shows promise for Diamond Blackfan anemia
  findings: []
- reference: DOI:10.1172/jci.insight.172475
  title: An atypical form of 60S ribosomal subunit in Diamond-Blackfan anemia linked to RPL17 variants
  findings: []
- reference: DOI:10.3390/cells13110920
  title: 'Towards a Cure for Diamond–Blackfan Anemia: Views on Gene Therapy'
  findings: []
- reference: DOI:10.3390/children10111812
  title: 'The Diverse Genomic Landscape of Diamond–Blackfan Anemia: Two Novel Variants and a Mini-Review'
  findings: []
📚

References & Deep Research

References

9
PMID:20301769
DBA Syndrome.
No top-level findings curated for this source.
DOI:10.1016/j.isci.2024.109172
Disruption of mitochondrial energy metabolism is a putative pathogenesis of Diamond-Blackfan anemia
No top-level findings curated for this source.
DOI:10.1016/j.jbc.2024.107542
Activation of nemo-like kinase in diamond blackfan anemia suppresses early erythropoiesis by preventing mitochondrial biogenesis
No top-level findings curated for this source.
DOI:10.1038/s41375-023-02082-w
Perspectives of current understanding and therapeutics of Diamond-Blackfan anemia
No top-level findings curated for this source.
DOI:10.1038/s41392-024-02033-6
BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK signaling
No top-level findings curated for this source.
DOI:10.1172/jci.insight.171650
Lentivirus-mediated gene therapy corrects ribosomal biogenesis and shows promise for Diamond Blackfan anemia
No top-level findings curated for this source.
DOI:10.1172/jci.insight.172475
An atypical form of 60S ribosomal subunit in Diamond-Blackfan anemia linked to RPL17 variants
No top-level findings curated for this source.
DOI:10.3390/cells13110920
Towards a Cure for Diamond–Blackfan Anemia: Views on Gene Therapy
No top-level findings curated for this source.
DOI:10.3390/children10111812
The Diverse Genomic Landscape of Diamond–Blackfan Anemia: Two Novel Variants and a Mini-Review
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Diamond-Blackfan Anemia
  • Category: Mendelian
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 34

Key Pathophysiology Nodes

  • Ribosomal Protein Haploinsufficiency
  • p53-Mediated Erythroid Apoptosis
  • GATA1 Translational Insufficiency
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1016/j.isci.2024.109172
  • DOI:10.1016/j.jbc.2024.107542
  • DOI:10.1016/s2352-3026(24
  • DOI:10.1038/s41375-023-02082-w
  • DOI:10.1038/s41392-024-02033-6
  • DOI:10.1172/jci.insight.171650
  • DOI:10.1172/jci.insight.172475
  • DOI:10.3390/cells13110920
  • DOI:10.3390/children10111812
Falcon ▸
Disease Pathophysiology Research Template
Edison Scientific Literature 35 citations 2026-02-15T22:03:09.633857

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Diamond-Blackfan Anemia
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Diamond-Blackfan Anemia. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Diamond–Blackfan anemia (DBA) pathophysiology research report (molecular/cellular focus)

0. Disease identifiers and scope

  • Disease: Diamond–Blackfan anemia (DBA) / “DBA syndrome” (expanded phenotype concept in 2024 consensus). (wlodarski2024diagnosistreatmentand pages 3-5)
  • MONDO: MONDO_0015253 (Diamond-Blackfan anemia). (liu2024perspectivesofcurrent pages 3-4)
  • Category: Mendelian, primarily autosomal dominant haploinsufficiency of ribosomal protein (RP) genes; additional X-linked and recessive DBA/DBA-like entities exist. (liu2024perspectivesofcurrent pages 1-2, pelagiadis2023thediversegenomic pages 1-2)

1. Key concepts, definitions, and current understanding (2023–2024)

1.1 Core definition (hematologic phenotype)

DBA is a congenital bone marrow failure disorder with selective erythroid hypoplasia and typically macrocytic, reticulocytopenic anemia. The 2024 international consensus defines DBA diagnosis by either (i) a pathogenic/likely pathogenic variant in a DBA gene or (ii) compatible hematologic findings including “macrocytic anemia… with reticulocytopenia and BM erythroblastopenia; absence of dysplasia, dyserythropoiesis, and sideroblasts” plus exclusion of differential diagnoses. (wlodarski2024diagnosistreatmentand pages 20-23)

1.2 DBA as a “ribosomopathy”

DBA is considered a prototypic ribosomopathy, usually caused by heterozygous RP gene variants that impair ribosome biogenesis (rRNA processing/maturation and/or subunit assembly). A 2024 review notes: “Around 75% of cases of DBA are related to a heterozygous allelic variation in ribosomal protein (RP) genes” and “mutations in 23 RP genes have been identified.” (liu2024perspectivesofcurrent pages 1-2)

1.3 Multi-hit molecular pathophysiology model

Current syntheses emphasize that impaired erythropoiesis results from several interacting stress programs downstream of RP haploinsufficiency, including p53 activation, translational dysfunction, inflammation, globin/heme imbalance with ROS, and autophagy/mitochondrial/metabolic perturbations. (liu2024perspectivesofcurrent pages 1-2, liu2024perspectivesofcurrent pages 3-4, pelagiadis2023thediversegenomic pages 5-8)

2. Core pathophysiology (molecular pathways and cellular processes)

2.1 Primary lesion: impaired ribosome biogenesis and rRNA processing

Mechanism. Pathogenic RP variants reduce effective ribosome production (“ribosomal insufficiency”), causing pre-rRNA processing defects and altered ribosomal subunit maturation. (liu2024perspectivesofcurrent pages 1-2, pelagiadis2023thediversegenomic pages 1-2)

Recent mechanistic example (2024, RPL17). In DBA pedigrees with RPL17 variants, patient-derived lines showed rRNA maturation defects and atypical large subunits: “5.8SC consisted of 8% to 21% of 5.8S rRNAs in affected case-derived cells,” and 10–20% of 60S subunits carried this short 5.8S rRNA species yet remained translationally active. (fellmann2024anatypicalform pages 1-2, fellmann2024anatypicalform pages 6-9)

Pathway-level consequence. Reduced ribosome output acts as a bottleneck for high-demand erythroid differentiation, driving lineage-selective failure of erythroid progenitors/precursors. (liu2024perspectivesofcurrent pages 1-2, fellmann2024anatypicalform pages 1-2)

2.2 Ribosomal/nucleolar stress → MDM2 inhibition → p53 stabilization

A central model is that disrupted ribosome biogenesis triggers nucleolar stress, leading to p53 stabilization (classically via RP/5S RNP interactions with MDM2). The 2023 mini-review summarizes defective rRNA maturation provoking nucleolar stress and p53 stabilization/activation, causing erythroid-specific arrest/apoptosis. (pelagiadis2023thediversegenomic pages 1-2)

The RPL17 JCI Insight paper situates its findings in the broader DBA framework whereby defective biogenesis leads to free 5S RNP binding and deactivation of HDM2/MDM2, stabilizing p53 and contributing to progenitor proliferation arrest and anemia. (fellmann2024anatypicalform pages 1-2)

2.3 Translational dysfunction and erythroid selectivity (GATA1 as a key node)

Beyond a modest global translation reduction, DBA exhibits selective translational vulnerability of key erythroid regulators. - A 2023 mini-review states: “Haploinsufficiency in RPs results in an impaired translation of GATA1 mRNA.” (pelagiadis2023thediversegenomic pages 5-8) - A 2024 review explains that GATA1 can be reduced via splice-site mutations and also by poor translation attributable to a structured 5′UTR, linking ribosome shortage to erythroid-specific defects. (liu2024perspectivesofcurrent pages 3-4)

2.4 Imbalanced globin/heme synthesis, oxidative stress, and apoptosis

Multiple sources converge on a model in which RP/GATA1 perturbations dysregulate globin–heme coordination, leading to free heme toxicity and ROS. - The 2023 review links reduced GATA1/RP deficiency to globin–heme imbalance and “accumulation of free cytoplasmic heme in erythroid progenitors, increasing the p53-dependent apoptosis” underlying erythroid failure. (pelagiadis2023thediversegenomic pages 5-8) - Additional supportive framing includes ROS contribution to defective erythropoiesis. (pelagiadis2023thediversegenomic pages 1-2)

2.5 Inflammatory signaling as a modifier/amplifier

A 2024 Leukemia review notes elevated inflammatory cytokines (e.g., IFN-γ, TNF-α) and enrichment of TNFα/NF-κB signatures (e.g., in RPS19-deficient CD34+ cells), consistent with inflammation contributing to marrow suppression and erythroid failure. (liu2024perspectivesofcurrent pages 3-4)

2.6 Autophagy/mitophagy and mitochondrial/metabolic mechanisms (rapidly developing area, 2024)

Two 2024 primary studies highlight mitochondrial control points that may interact with ribosome biogenesis and translation:

(i) OXPHOS → ribosome biogenesis coupling (iScience, Mar 2024). OXPHOS suppression in a primary HSPC-to-erythroid model caused erythroid differentiation failure and ribosome biogenesis defects; RanGAP1 was identified as an OXPHOS-dependent mediator and coenzyme Q10 (CoQ10) activation of OXPHOS rescued erythroid defects. Patient data suggested OXPHOS suppression with reduced ribosome biogenesis and that OXPHOS gene mutations (~10%) might contribute. (xiao2024disruptionofmitochondrial pages 1-2)

(ii) NLK–mTORC1–mitochondrial biogenesis axis (JBC, Aug 2024). In erythroid progenitors from DBA patients, NLK is “hyperactivated” and suppresses mTORC1 via Raptor phosphorylation. The authors state: “NLK-mediated phosphorylation of Raptor suppresses mTORC1 activity” and “Phosphorylation of Raptor at S863 prevents mTORC1 from localizing to the outer lysosomal membrane where the complex is activated by Rheb.” This suppresses translation of mitochondrial biogenesis factors and impairs early erythropoiesis. (wilkes2024activationofnemolike pages 1-2)

3. Key molecular players (genes/proteins), chemical entities, cell types, and anatomic sites

3.1 Causal/implicated genes (HGNC symbols) and roles

Major RP genes (examples; not exhaustive): - RPS19 (most frequent; commonly cited ~25% of cases). (liu2024perspectivesofcurrent pages 1-2, gimenez2024lentivirusmediatedgenetherapy pages 1-2) - RPL5, RPL11, RPS26, RPS24 (frequent; linked to congenital anomalies and other genotype–phenotype differences). (liu2024perspectivesofcurrent pages 1-2, liu2024perspectivesofcurrent pages 2-3) - RPL17 (2024: causes atypical 60S/5.8S rRNA phenotype). (fellmann2024anatypicalform pages 1-2, fellmann2024anatypicalform pages 6-9)

Non-RP DBA/DBA-like genes discussed in recent synthesis: - GATA1 (erythroid TF; splice mutations and translation sensitivity). (liu2024perspectivesofcurrent pages 1-2, liu2024perspectivesofcurrent pages 3-4) - TSR2 (RPS26 chaperone; X-linked DBA-like). (liu2024perspectivesofcurrent pages 3-4, pelagiadis2023thediversegenomic pages 1-2) - HEATR3 (ribosome biogenesis factor; variants can reduce nuclear uL18/RPL5 and impair ribosome biogenesis, described as potentially p53-independent in parts of the pathway). (liu2024perspectivesofcurrent pages 3-4) - EPO (rare recessive DBA-like; altered receptor affinity described in review). (liu2024perspectivesofcurrent pages 3-4) - CECR1 / ADA2 (DBA-like; clinically relevant as HSCT may be effective). (pelagiadis2023thediversegenomic pages 5-8) - TP53 gain-of-function (rare DBA-like phenotypes discussed in consensus context). (wlodarski2024diagnosistreatmentand pages 16-18, wlodarski2024diagnosistreatmentand pages 3-5)

3.2 Key pathways (GO-style biological process labels)

Ontology-ready GO biological process descriptors supported by the cited evidence include: - Ribosome biogenesis / ribosomal large/small subunit assembly / rRNA processing (including pre-rRNA cleavage steps). (liu2024perspectivesofcurrent pages 1-2, fellmann2024anatypicalform pages 6-9) - Nucleolar stress response leading to p53-mediated apoptotic signaling and cell cycle arrest. (pelagiadis2023thediversegenomic pages 1-2, fellmann2024anatypicalform pages 1-2) - Regulation of translation (global and selective translation; GATA1 sensitivity). (liu2024perspectivesofcurrent pages 3-4, pelagiadis2023thediversegenomic pages 5-8) - Erythrocyte differentiation / erythropoiesis (failure of progenitor expansion/maturation). (liu2024perspectivesofcurrent pages 1-2, wu2024brafinhibitorsenhance pages 1-2) - Response to oxidative stress and heme metabolic process (free heme → ROS → apoptosis model). (pelagiadis2023thediversegenomic pages 5-8) - Inflammatory response / NF-κB signaling / TNF signaling (as modifiers). (liu2024perspectivesofcurrent pages 3-4) - Mitochondrial biogenesis and oxidative phosphorylation as modulators of erythroid commitment and ribosome output. (xiao2024disruptionofmitochondrial pages 1-2, wilkes2024activationofnemolike pages 1-2)

3.3 Cellular components (GO cellular component labels)

Ontology-ready cellular component descriptors include: - Nucleolus (site of rRNA transcription/processing and early ribosome biogenesis; nucleolar stress trigger). (pelagiadis2023thediversegenomic pages 1-2, fellmann2024anatypicalform pages 6-9) - Ribosome (40S/60S subunits; atypical 60S with altered 5.8S rRNA in RPL17 DBA). (fellmann2024anatypicalform pages 1-2) - Cytosol (translation; globin/heme imbalance effects). (pelagiadis2023thediversegenomic pages 5-8) - Mitochondrion (OXPHOS; mitochondrial biogenesis/mitophagy programs affecting erythropoiesis). (xiao2024disruptionofmitochondrial pages 1-2, wilkes2024activationofnemolike pages 1-2) - Lysosomal membrane (mTORC1 activation platform; Raptor phosphorylation affecting localization). (wilkes2024activationofnemolike pages 1-2)

3.4 Key cell types (CL-style)

Primary affected hematopoietic populations include: - Hematopoietic stem and progenitor cells (HSPCs) and early erythroid progenitors. (xiao2024disruptionofmitochondrial pages 1-2, wu2024brafinhibitorsenhance pages 1-2) - Erythroid progenitors/precursors (reduced in marrow; early erythropoiesis block). (liu2024perspectivesofcurrent pages 1-2, wlodarski2024diagnosistreatmentand pages 20-23)

3.5 Anatomical locations (UBERON-style)

  • Bone marrow (erythroblastopenia; diagnostic site). (wlodarski2024diagnosistreatmentand pages 20-23)
  • Peripheral blood (macrocytosis, reticulocytopenia; HbF/eADA biomarkers). (wlodarski2024diagnosistreatmentand pages 20-23, liu2024perspectivesofcurrent pages 2-3)

3.6 Chemical entities (CHEBI-style)

  • L-leucine (branched-chain amino acid; translation/mTOR-targeted strategy; clinical trial NCT01362595). (NCT01362595 chunk 1)
  • Coenzyme Q10 (ubiquinone) (OXPHOS activator; rescued erythroid defects in model). (xiao2024disruptionofmitochondrial pages 1-2)
  • BRAF inhibitors (drug class; paradoxical MAPK activation enhances erythropoiesis, including DBA samples/models). (wu2024brafinhibitorsenhance pages 1-2)
  • Prednisone/prednisolone (glucocorticoids; standard-of-care). (wlodarski2024diagnosistreatmentand pages 8-10)
  • Iron chelators: deferoxamine (DFO), deferasirox (DFX), deferiprone (DFP). (wlodarski2024diagnosistreatmentand pages 10-11)

4. Disease progression model (sequence of events)

A knowledge-base-ready sequence supported by 2023–2024 evidence: 1. Germline RP haploinsufficiency (or specific non-RP gene defects) reduces effective ribosome biogenesis and/or alters rRNA processing and ribosome output. (liu2024perspectivesofcurrent pages 1-2, pelagiadis2023thediversegenomic pages 1-2, fellmann2024anatypicalform pages 6-9) 2. Ribosomal/nucleolar stress activates p53 programs via MDM2 inhibition (canonical model), promoting progenitor cell cycle arrest/apoptosis. (pelagiadis2023thediversegenomic pages 1-2, fellmann2024anatypicalform pages 1-2) 3. Selective translational insufficiency reduces key erythroid regulators such as GATA1, compromising erythroid lineage specification and maturation. (pelagiadis2023thediversegenomic pages 5-8, liu2024perspectivesofcurrent pages 3-4) 4. Downstream metabolic and proteostatic stress emerges, including globin/heme imbalance (free heme → ROS) and potentially autophagy/mitochondrial dysfunction. (pelagiadis2023thediversegenomic pages 5-8, liu2024perspectivesofcurrent pages 3-4) 5. Failure of early erythropoiesis manifests as marrow erythroid hypoplasia/erythroblastopenia and reticulocytopenic anemia, with variable congenital anomalies and cancer predisposition. (wlodarski2024diagnosistreatmentand pages 20-23, liu2024perspectivesofcurrent pages 1-2)

5. Phenotypic manifestations and mechanistic links (HP-style)

Common/important clinical phenotypes and their mechanistic relationships: - Macrocytic anemia and reticulocytopenia: direct consequence of erythroid progenitor depletion and maturation failure. (wlodarski2024diagnosistreatmentand pages 20-23) - Bone marrow erythroblastopenia: defining tissue phenotype consistent with early erythroid block. (wlodarski2024diagnosistreatmentand pages 20-23) - Congenital anomalies (subset): genotype–phenotype correlations show higher malformation rates with some large subunit genes (e.g., RPL5/RPL11) than with RPS19 in recent review synthesis. (liu2024perspectivesofcurrent pages 2-3) - Cancer predisposition (MDS/AML and solid tumors including colon cancer): increased risk is recognized and drives lifelong surveillance recommendations. (liu2024perspectivesofcurrent pages 1-2, pelagiadis2023thediversegenomic pages 1-2, wlodarski2024diagnosistreatmentand pages 3-5)

6. Recent developments (2023–2024) and latest research highlights

6.1 Ribosome structural/processing diversity in DBA (2024)

RPL17 DBA can yield an atypical translated ribosome pool with altered 5.8S rRNA length and measurable pre-rRNA processing changes, reinforcing that DBA can involve both quantity (ribosome abundance) and qualitative rRNA processing perturbations. (fellmann2024anatypicalform pages 1-2, fellmann2024anatypicalform pages 6-9)

6.2 Mitochondrial energy metabolism as a mechanistic contributor and potential target (2024)

A primary mechanistic proposal is that OXPHOS suppression can impair ribosome biogenesis and erythroid differentiation, with RanGAP1 as a mediator and CoQ10 as a rescuing intervention in model systems; patient transcriptomics suggest an OXPHOS-gene mutation signal (~10%). (xiao2024disruptionofmitochondrial pages 1-2)

6.3 Kinase signaling control of mitochondrial biogenesis in DBA (2024)

NLK hyperactivation suppresses mTORC1 and blocks translation of mitochondrial biogenesis factors (e.g., TFAM, PHB2 protein upregulation is translation-controlled), connecting ribosome insufficiency to a specific kinase→mTORC1→mitochondrial biogenesis bottleneck in early erythropoiesis. (wilkes2024activationofnemolike pages 1-2)

6.4 Small-molecule pathway modulation: paradoxical MAPK activation by BRAF inhibitors (2024)

A 2024 Signal Transduction and Targeted Therapy study reported that BRAF inhibitors can act as MAPK “amplifiers” in WT BRAF contexts, boosting progenitor proliferation; “overall cell numbers [increased] by nearly 10-fold” in culture and activity was observed in DBA patient samples and an Rpl11 haploinsufficiency DBA model. (wu2024brafinhibitorsenhance pages 1-2)

6.5 Gene therapy trajectory (2024)

Lentiviral gene addition remains a leading experimental curative approach for RPS19-deficient DBA: - A 2024 JCI Insight paper developed clinically applicable vectors (PGK.CoRPS19, EF1α.CoRPS19) and reported restoration of erythroid differentiation in patient CD34+ cells plus long-term repopulating properties and non-toxic insertion-site/safety profiles. (gimenez2024lentivirusmediatedgenetherapy pages 1-2) - A 2024 Cells review summarizes preclinical evidence that enforced RPS19 expression can “cure” anemia and prevent lethal marrow failure in mouse models and supports the rationale for autologous gene therapy to circumvent donor limitations of allogeneic HSCT. (vale2024towardsacure pages 4-6)

7. Current applications and real-world implementations (clinical practice)

7.1 Diagnostic implementation (2024 consensus)

Practical diagnostic approach includes genetic confirmation or classic hematology/BM findings with exclusion of mimics (TEC, viral PRCA, MDS with 5q-, other inherited bone marrow failure syndromes, Pearson syndrome, congenital sideroblastic/dyserythropoietic anemias). (wlodarski2024diagnosistreatmentand pages 20-23)

7.2 First-line therapy: corticosteroids

The 2024 international consensus provides specific implementation details: - Initial prednisone/prednisolone: 2 mg/kg/day (with max limits) and avoid extending the initial high-dose course beyond ~4 weeks; assess reticulocyte/Hb response at ~10–14 days. (wlodarski2024diagnosistreatmentand pages 8-10) - Initial steroid response rate ~60–80%; ~30–40% remain on durable steroid therapy. (wlodarski2024diagnosistreatmentand pages 8-10)

7.3 Chronic transfusion strategy and iron overload management

The 2024 consensus recommends higher transfusion targets than restrictive adult triggers: maintain pre-transfusion nadir ≥9–10 g/dL to support growth and quality of life, often using q3-week schedules. (wlodarski2024diagnosistreatmentand pages 8-10)

Because transfusions are the major iron source and iron overload is a major cause of death in non-transplanted patients, the consensus emphasizes MRI-based monitoring and quantitative targets/thresholds (e.g., LIC goal <3 mg Fe/g dry weight; cardiac T2* thresholds). (wlodarski2024diagnosistreatmentand pages 10-11)

7.4 Curative therapy: HSCT (and movement toward gene therapy)

  • HSCT remains the only established curative option for hematologic disease in DBA in current standard practice, but is limited by donor availability and transplant risks; consensus broadens HSCT indications and emphasizes systematic surveillance. (liu2024perspectivesofcurrent pages 1-2, wlodarski2024diagnosistreatmentand pages 3-5)
  • Gene therapy is an active translational direction for RPS19 DBA, supported by 2024 preclinical human CD34+ correction and vector safety analyses. (gimenez2024lentivirusmediatedgenetherapy pages 1-2)

7.5 Clinical trials and experimental therapeutics (implementation evidence)

L-leucine (ClinicalTrials.gov). NCT01362595 (Northwell Health) is a single-group, open-label Phase I/II trial in transfusion-dependent DBA. Dose: 700 mg/m² per dose, orally three times daily; primary efficacy endpoint at 9 months; enrollment 55; results posted 2022-12-02. (NCT01362595 chunk 1)

8. Expert opinions and authoritative analyses (2024 consensus and high-impact reviews)

  • The 2024 Lancet Haematology consensus explicitly states that the evidence base is largely non-randomized (“level C”) and therefore provides expert-derived implementation thresholds (transfusion Hb targets, steroid dose ceilings, iron MRI targets, and systematic surveillance including early colorectal cancer screening). (wlodarski2024diagnosistreatmentand pages 3-5)
  • The 2024 Leukemia review frames DBA as a multi-mechanism disorder and highlights emerging therapeutics (notably gene therapy for RPS19) while emphasizing unresolved questions such as erythroid lineage selectivity and variable penetrance/remission. (liu2024perspectivesofcurrent pages 1-2)

9. Relevant recent statistics and data (2023–2024)

9.1 Epidemiology

  • Incidence estimates:
  • ~5–7 cases per million live births (2024 review). (liu2024perspectivesofcurrent pages 1-2)
  • ~5–10 cases per million live births (2024 international consensus). (wlodarski2024diagnosistreatmentand pages 3-5)
  • Alternative expression in one 2024 primary paper: ~1 in 100,000–200,000 births. (fellmann2024anatypicalform pages 1-2)

9.2 Genetics (frequency highlights)

  • Proportion with RP-gene involvement: ~75% RP genes; ~70–80% have putatively causal haploinsufficient variants in some series/framings. (liu2024perspectivesofcurrent pages 1-2)
  • RPS19 ~25% of cases (commonly cited). (liu2024perspectivesofcurrent pages 1-2, gimenez2024lentivirusmediatedgenetherapy pages 1-2)

9.3 Biomarkers and genotype–phenotype

  • eADA elevation in ~80–85% of patients (review synthesis) and is a supportive diagnostic criterion in the 2024 consensus. (liu2024perspectivesofcurrent pages 2-3, wlodarski2024diagnosistreatmentand pages 20-23)
  • Genotype–phenotype example: malformations are more frequent with RPL5/RPL11 compared with RPS19 in review summaries. (liu2024perspectivesofcurrent pages 2-3)

9.4 Treatment outcomes

  • Steroid response: initial response ~60–80%. (wlodarski2024diagnosistreatmentand pages 8-10)
  • Treatment independence: French registry (n=222) 21% overall, 30% if initially steroid responsive, 5% if steroid non-responsive; ~70% of independence achieved in first decade. (wlodarski2024diagnosistreatmentand pages 10-11)

9.5 Malignancy risk

  • A 2023 mini-review reports 4.8-fold increased cancer risk and ~20% cumulative incidence of malignancy/MDS/AML by age 46. (pelagiadis2023thediversegenomic pages 1-2)

10. Knowledge-base-ready annotation blocks

10.1 Gene/protein annotations (HGNC symbols) with mechanistic tags

  • RPS19, RPL5, RPL11, RPS26, RPS24, RPL17: ribosome biogenesis/rRNA maturation; ribosomal stress; p53 pathway activation; erythroid differentiation failure. (liu2024perspectivesofcurrent pages 1-2, fellmann2024anatypicalform pages 1-2)
  • GATA1: erythroid transcription program; translationally sensitive node in ribosome insufficiency. (liu2024perspectivesofcurrent pages 3-4, pelagiadis2023thediversegenomic pages 5-8)
  • HEATR3, TSR2: ribosome biogenesis/assembly factors (DBA-like). (liu2024perspectivesofcurrent pages 3-4)
  • TP53: rare gain-of-function DBA-like; central stress effector. (wlodarski2024diagnosistreatmentand pages 16-18)
  • NLK, RPTOR (Raptor), MTOR: signaling module linking DBA stress to mTORC1 inhibition and mitochondrial biogenesis block. (wilkes2024activationofnemolike pages 1-2)
  • RanGAP1: OXPHOS-dependent mediator connecting mitochondrial metabolism to ribosome biogenesis in model. (xiao2024disruptionofmitochondrial pages 1-2)

10.2 GO biological process candidates (text labels)

  • ribosome biogenesis; rRNA processing; translation; regulation of translation; erythrocyte differentiation/erythropoiesis; p53-mediated apoptotic signaling; response to oxidative stress; mitochondrial oxidative phosphorylation; mitochondrial biogenesis; inflammatory response/NF-κB signaling. (liu2024perspectivesofcurrent pages 3-4, fellmann2024anatypicalform pages 6-9, xiao2024disruptionofmitochondrial pages 1-2, wilkes2024activationofnemolike pages 1-2)

10.3 CL cell type candidates (text labels)

  • hematopoietic stem cell; hematopoietic progenitor cell; erythroid progenitor cell; erythroblast. (xiao2024disruptionofmitochondrial pages 1-2, wlodarski2024diagnosistreatmentand pages 20-23)

10.4 UBERON anatomy candidates (text labels)

  • bone marrow; blood. (wlodarski2024diagnosistreatmentand pages 20-23)

10.5 HP phenotype candidates (text labels)

  • macrocytic anemia; reticulocytopenia; erythroblastopenia; congenital anomalies (craniofacial/limb/cardiac); cancer predisposition; growth impairment. (wlodarski2024diagnosistreatmentand pages 20-23, liu2024perspectivesofcurrent pages 1-2)

10.6 CHEBI chemical candidates (text labels)

  • L-leucine; coenzyme Q10 (ubiquinone); prednisone/prednisolone; deferoxamine/deferasirox/deferiprone; BRAF inhibitors. (NCT01362595 chunk 1, xiao2024disruptionofmitochondrial pages 1-2, wlodarski2024diagnosistreatmentand pages 8-10, wlodarski2024diagnosistreatmentand pages 10-11, wu2024brafinhibitorsenhance pages 1-2)

11. Evidence items (PMID-focused) and limitations

The provided 2023–2024 evidence extracts are primarily from full-text/registry materials indexed by DOI and trial identifiers, and many excerpts did not include PubMed IDs in the available text. Where PMIDs are required for mechanistic claims, additional targeted PubMed retrieval would be needed to map each mechanistic statement to a PMID explicitly (particularly for classic p53/MDM2/5S-RNP literature). Within the available context, mechanistic claims are supported by peer-reviewed primary papers and consensus/reviews with DOI/URLs (listed above) and ClinicalTrials.gov identifiers. (wlodarski2024diagnosistreatmentand pages 3-5, fellmann2024anatypicalform pages 1-2, xiao2024disruptionofmitochondrial pages 1-2, wilkes2024activationofnemolike pages 1-2, NCT01362595 chunk 1)

12. Key source list (URLs and publication dates)

  • Wlodarski MW et al. May 2024. The Lancet Haematology (international consensus). https://doi.org/10.1016/S2352-3026(24)00063-2 (wlodarski2024diagnosistreatmentand pages 3-5)
  • Liu Y, Karlsson S. Nov 2024. Leukemia (review). https://doi.org/10.1038/s41375-023-02082-w (liu2024perspectivesofcurrent pages 1-2)
  • Fellmann F et al. Aug 2024. JCI Insight (RPL17 atypical 60S). https://doi.org/10.1172/jci.insight.172475 (fellmann2024anatypicalform pages 1-2)
  • Wilkes MC et al. Aug 2024. J Biol Chem (NLK–mTORC1–mitochondria). https://doi.org/10.1016/j.jbc.2024.107542 (wilkes2024activationofnemolike pages 1-2)
  • Xiao R et al. Mar 2024. iScience (OXPHOS/RanGAP1/CoQ10). https://doi.org/10.1016/j.isci.2024.109172 (xiao2024disruptionofmitochondrial pages 1-2)
  • Wu S et al. Dec 2024. Signal Transduction and Targeted Therapy (BRAFi/MAPK/erythropoiesis). https://doi.org/10.1038/s41392-024-02033-6 (wu2024brafinhibitorsenhance pages 1-2)
  • Giménez Y et al. May 2024. JCI Insight (RPS19 lentiviral gene therapy). https://doi.org/10.1172/jci.insight.171650 (gimenez2024lentivirusmediatedgenetherapy pages 1-2)
  • ClinicalTrials.gov NCT01362595 (LeucineDBA). Results posted Dec 2, 2022; started Jun 2013. https://clinicaltrials.gov/study/NCT01362595 (NCT01362595 chunk 1)

References

  1. (wlodarski2024diagnosistreatmentand pages 3-5): Marcin W Wlodarski, Adrianna Vlachos, Jason E Farrar, Lydie M Da Costa, Antonis Kattamis, Irma Dianzani, Cristina Belendez, Sule Unal, Hannah Tamary, Ramune Pasauliene, Dagmar Pospisilova, Josu de la Fuente, Deena Iskander, Lawrence Wolfe, Johnson M Liu, Akiko Shimamura, Katarzyna Albrecht, Birgitte Lausen, Anne Grete Bechensteen, Ulf Tedgard, Alexander Puzik, Paola Quarello, Ugo Ramenghi, Marije Bartels, Heinz Hengartner, Roula A Farah, Mahasen Al Saleh, Amir Ali Hamidieh, Wan Yang, Etsuro Ito, Hoon Kook, Galina Ovsyannikova, Leo Kager, Pierre-Emmanuel Gleizes, Jean-Hugues Dalle, Brigitte Strahm, Charlotte M Niemeyer, Jeffrey M Lipton, and Thierry M Leblanc. Diagnosis, treatment, and surveillance of diamond-blackfan anaemia syndrome: international consensus statement. The Lancet. Haematology, 11 5:e368-e382, May 2024. URL: https://doi.org/10.1016/s2352-3026(24)00063-2, doi:10.1016/s2352-3026(24)00063-2. This article has 48 citations.

  2. (liu2024perspectivesofcurrent pages 3-4): Yang Liu and Stefan Karlsson. Perspectives of current understanding and therapeutics of diamond-blackfan anemia. Leukemia, 38:1-9, Nov 2024. URL: https://doi.org/10.1038/s41375-023-02082-w, doi:10.1038/s41375-023-02082-w. This article has 52 citations and is from a highest quality peer-reviewed journal.

  3. (liu2024perspectivesofcurrent pages 1-2): Yang Liu and Stefan Karlsson. Perspectives of current understanding and therapeutics of diamond-blackfan anemia. Leukemia, 38:1-9, Nov 2024. URL: https://doi.org/10.1038/s41375-023-02082-w, doi:10.1038/s41375-023-02082-w. This article has 52 citations and is from a highest quality peer-reviewed journal.

  4. (pelagiadis2023thediversegenomic pages 1-2): Iordanis Pelagiadis, Ioannis Kyriakidis, Nikolaos Katzilakis, Chrysoula Kosmeri, Danai Veltra, Christalena Sofocleous, Stavros Glentis, Antonis Kattamis, Alexandros Makis, and Eftichia Stiakaki. The diverse genomic landscape of diamond–blackfan anemia: two novel variants and a mini-review. Children, 10:1812, Nov 2023. URL: https://doi.org/10.3390/children10111812, doi:10.3390/children10111812. This article has 4 citations.

  5. (wlodarski2024diagnosistreatmentand pages 20-23): Marcin W Wlodarski, Adrianna Vlachos, Jason E Farrar, Lydie M Da Costa, Antonis Kattamis, Irma Dianzani, Cristina Belendez, Sule Unal, Hannah Tamary, Ramune Pasauliene, Dagmar Pospisilova, Josu de la Fuente, Deena Iskander, Lawrence Wolfe, Johnson M Liu, Akiko Shimamura, Katarzyna Albrecht, Birgitte Lausen, Anne Grete Bechensteen, Ulf Tedgard, Alexander Puzik, Paola Quarello, Ugo Ramenghi, Marije Bartels, Heinz Hengartner, Roula A Farah, Mahasen Al Saleh, Amir Ali Hamidieh, Wan Yang, Etsuro Ito, Hoon Kook, Galina Ovsyannikova, Leo Kager, Pierre-Emmanuel Gleizes, Jean-Hugues Dalle, Brigitte Strahm, Charlotte M Niemeyer, Jeffrey M Lipton, and Thierry M Leblanc. Diagnosis, treatment, and surveillance of diamond-blackfan anaemia syndrome: international consensus statement. The Lancet. Haematology, 11 5:e368-e382, May 2024. URL: https://doi.org/10.1016/s2352-3026(24)00063-2, doi:10.1016/s2352-3026(24)00063-2. This article has 48 citations.

  6. (pelagiadis2023thediversegenomic pages 5-8): Iordanis Pelagiadis, Ioannis Kyriakidis, Nikolaos Katzilakis, Chrysoula Kosmeri, Danai Veltra, Christalena Sofocleous, Stavros Glentis, Antonis Kattamis, Alexandros Makis, and Eftichia Stiakaki. The diverse genomic landscape of diamond–blackfan anemia: two novel variants and a mini-review. Children, 10:1812, Nov 2023. URL: https://doi.org/10.3390/children10111812, doi:10.3390/children10111812. This article has 4 citations.

  7. (fellmann2024anatypicalform pages 1-2): Florence Fellmann, Carol Saunders, Marie-Françoise O’Donohue, David W. Reid, Kelsey A. McFadden, Nathalie Montel-Lehry, Cong Yu, Mingyan Fang, Jianguo Zhang, Beryl Royer-Bertrand, Pietro Farinelli, Narjesse Karboul, Jason R. Willer, Lorraine Fievet, Zahurul Alam Bhuiyan, Alissa L.W. Kleinhenz, Julie Jadeau, Joy Fulbright, Carlo Rivolta, Raffaele Renella, Nicholas Katsanis, Jacques S. Beckmann, Christopher V. Nicchitta, Lydie Da Costa, Erica E. Davis, and Pierre-Emmanuel Gleizes. An atypical form of 60s ribosomal subunit in diamond-blackfan anemia linked to rpl17 variants. JCI Insight, Aug 2024. URL: https://doi.org/10.1172/jci.insight.172475, doi:10.1172/jci.insight.172475. This article has 2 citations and is from a domain leading peer-reviewed journal.

  8. (fellmann2024anatypicalform pages 6-9): Florence Fellmann, Carol Saunders, Marie-Françoise O’Donohue, David W. Reid, Kelsey A. McFadden, Nathalie Montel-Lehry, Cong Yu, Mingyan Fang, Jianguo Zhang, Beryl Royer-Bertrand, Pietro Farinelli, Narjesse Karboul, Jason R. Willer, Lorraine Fievet, Zahurul Alam Bhuiyan, Alissa L.W. Kleinhenz, Julie Jadeau, Joy Fulbright, Carlo Rivolta, Raffaele Renella, Nicholas Katsanis, Jacques S. Beckmann, Christopher V. Nicchitta, Lydie Da Costa, Erica E. Davis, and Pierre-Emmanuel Gleizes. An atypical form of 60s ribosomal subunit in diamond-blackfan anemia linked to rpl17 variants. JCI Insight, Aug 2024. URL: https://doi.org/10.1172/jci.insight.172475, doi:10.1172/jci.insight.172475. This article has 2 citations and is from a domain leading peer-reviewed journal.

  9. (xiao2024disruptionofmitochondrial pages 1-2): Rudan Xiao, Lijuan Zhang, Zijuan Xin, Junwei Zhu, Qian Zhang, Guangmin Zheng, Siyun Chu, Jing Wu, Lu Zhang, Yang Wan, Xiaojuan Chen, Weiping Yuan, Zhaojun Zhang, Xiaofan Zhu, and Xiangdong Fang. Disruption of mitochondrial energy metabolism is a putative pathogenesis of diamond-blackfan anemia. iScience, 27:109172, Mar 2024. URL: https://doi.org/10.1016/j.isci.2024.109172, doi:10.1016/j.isci.2024.109172. This article has 5 citations and is from a peer-reviewed journal.

  10. (wilkes2024activationofnemolike pages 1-2): Mark C. Wilkes, Aya Shibuya, Y. Lucy Liu, Kailen Mark, Jaqueline Mercado, Mallika Saxena, Ryan S. Sathianathen, Hye Na Kim, Bertil Glader, Paraic Kenny, and Kathleen M. Sakamoto. Activation of nemo-like kinase in diamond blackfan anemia suppresses early erythropoiesis by preventing mitochondrial biogenesis. Journal of Biological Chemistry, 300:107542, Aug 2024. URL: https://doi.org/10.1016/j.jbc.2024.107542, doi:10.1016/j.jbc.2024.107542. This article has 3 citations and is from a domain leading peer-reviewed journal.

  11. (gimenez2024lentivirusmediatedgenetherapy pages 1-2): Yari Giménez, Manuel Palacios, Rebeca Sánchez-Domínguez, Christiane Zorbas, Jorge Peral, Alexander Puzik, Laura Ugalde, Omaira Alberquilla, Mariela Villanueva, Paula Río, Eva Gálvez, Lydie Da Costa, Marion Strullu, Albert Catala, Anna Ruiz-Llobet, Jose Carlos Segovia, Julián Sevilla, Brigitte Strahm, Charlotte M. Niemeyer, Cristina Beléndez, Thierry Leblanc, Denis L.J. Lafontaine, Juan Bueren, and Susana Navarro. Lentivirus-mediated gene therapy corrects ribosomal biogenesis and shows promise for diamond blackfan anemia. JCI Insight, May 2024. URL: https://doi.org/10.1172/jci.insight.171650, doi:10.1172/jci.insight.171650. This article has 10 citations and is from a domain leading peer-reviewed journal.

  12. (liu2024perspectivesofcurrent pages 2-3): Yang Liu and Stefan Karlsson. Perspectives of current understanding and therapeutics of diamond-blackfan anemia. Leukemia, 38:1-9, Nov 2024. URL: https://doi.org/10.1038/s41375-023-02082-w, doi:10.1038/s41375-023-02082-w. This article has 52 citations and is from a highest quality peer-reviewed journal.

  13. (wlodarski2024diagnosistreatmentand pages 16-18): Marcin W Wlodarski, Adrianna Vlachos, Jason E Farrar, Lydie M Da Costa, Antonis Kattamis, Irma Dianzani, Cristina Belendez, Sule Unal, Hannah Tamary, Ramune Pasauliene, Dagmar Pospisilova, Josu de la Fuente, Deena Iskander, Lawrence Wolfe, Johnson M Liu, Akiko Shimamura, Katarzyna Albrecht, Birgitte Lausen, Anne Grete Bechensteen, Ulf Tedgard, Alexander Puzik, Paola Quarello, Ugo Ramenghi, Marije Bartels, Heinz Hengartner, Roula A Farah, Mahasen Al Saleh, Amir Ali Hamidieh, Wan Yang, Etsuro Ito, Hoon Kook, Galina Ovsyannikova, Leo Kager, Pierre-Emmanuel Gleizes, Jean-Hugues Dalle, Brigitte Strahm, Charlotte M Niemeyer, Jeffrey M Lipton, and Thierry M Leblanc. Diagnosis, treatment, and surveillance of diamond-blackfan anaemia syndrome: international consensus statement. The Lancet. Haematology, 11 5:e368-e382, May 2024. URL: https://doi.org/10.1016/s2352-3026(24)00063-2, doi:10.1016/s2352-3026(24)00063-2. This article has 48 citations.

  14. (wu2024brafinhibitorsenhance pages 1-2): Shunkang Wu, Yuelin Deng, Haobo Sun, Xuewen Liu, Shuo Zhou, Hanxi Zhao, Huan Li, Fusheng Guo, Qiuyu Yue, Fan Wu, Xinying Zhao, Na Li, Shicong Zhu, Qi Hu, Si Xie, Jie Zheng, Meng Lv, Yuan Kong, Xiao-Jun Huang, Xiaoguang Lei, Xiangmin Tong, Xiaofei Gao, and Hsiang-Ying Lee. Braf inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of mapk signaling. Signal Transduction and Targeted Therapy, Dec 2024. URL: https://doi.org/10.1038/s41392-024-02033-6, doi:10.1038/s41392-024-02033-6. This article has 6 citations and is from a peer-reviewed journal.

  15. (NCT01362595 chunk 1): Adrianna Vlachos, MD. Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia. Northwell Health. 2013. ClinicalTrials.gov Identifier: NCT01362595

  16. (wlodarski2024diagnosistreatmentand pages 8-10): Marcin W Wlodarski, Adrianna Vlachos, Jason E Farrar, Lydie M Da Costa, Antonis Kattamis, Irma Dianzani, Cristina Belendez, Sule Unal, Hannah Tamary, Ramune Pasauliene, Dagmar Pospisilova, Josu de la Fuente, Deena Iskander, Lawrence Wolfe, Johnson M Liu, Akiko Shimamura, Katarzyna Albrecht, Birgitte Lausen, Anne Grete Bechensteen, Ulf Tedgard, Alexander Puzik, Paola Quarello, Ugo Ramenghi, Marije Bartels, Heinz Hengartner, Roula A Farah, Mahasen Al Saleh, Amir Ali Hamidieh, Wan Yang, Etsuro Ito, Hoon Kook, Galina Ovsyannikova, Leo Kager, Pierre-Emmanuel Gleizes, Jean-Hugues Dalle, Brigitte Strahm, Charlotte M Niemeyer, Jeffrey M Lipton, and Thierry M Leblanc. Diagnosis, treatment, and surveillance of diamond-blackfan anaemia syndrome: international consensus statement. The Lancet. Haematology, 11 5:e368-e382, May 2024. URL: https://doi.org/10.1016/s2352-3026(24)00063-2, doi:10.1016/s2352-3026(24)00063-2. This article has 48 citations.

  17. (wlodarski2024diagnosistreatmentand pages 10-11): Marcin W Wlodarski, Adrianna Vlachos, Jason E Farrar, Lydie M Da Costa, Antonis Kattamis, Irma Dianzani, Cristina Belendez, Sule Unal, Hannah Tamary, Ramune Pasauliene, Dagmar Pospisilova, Josu de la Fuente, Deena Iskander, Lawrence Wolfe, Johnson M Liu, Akiko Shimamura, Katarzyna Albrecht, Birgitte Lausen, Anne Grete Bechensteen, Ulf Tedgard, Alexander Puzik, Paola Quarello, Ugo Ramenghi, Marije Bartels, Heinz Hengartner, Roula A Farah, Mahasen Al Saleh, Amir Ali Hamidieh, Wan Yang, Etsuro Ito, Hoon Kook, Galina Ovsyannikova, Leo Kager, Pierre-Emmanuel Gleizes, Jean-Hugues Dalle, Brigitte Strahm, Charlotte M Niemeyer, Jeffrey M Lipton, and Thierry M Leblanc. Diagnosis, treatment, and surveillance of diamond-blackfan anaemia syndrome: international consensus statement. The Lancet. Haematology, 11 5:e368-e382, May 2024. URL: https://doi.org/10.1016/s2352-3026(24)00063-2, doi:10.1016/s2352-3026(24)00063-2. This article has 48 citations.

  18. (vale2024towardsacure pages 4-6): Matilde Vale, Jan Prochazka, and Radislav Sedlacek. Towards a cure for diamond–blackfan anemia: views on gene therapy. Cells, 13:920, May 2024. URL: https://doi.org/10.3390/cells13110920, doi:10.3390/cells13110920. This article has 8 citations.